The Experts below are selected from a list of 1068 Experts worldwide ranked by ideXlab platform

Thomas M. Bashore - One of the best experts on this subject based on the ideXlab platform.

  • peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon Mitral Valve Commissurotomy
    Journal of Heart Valve Disease, 2006
    Co-Authors: R J Garr, Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Andrew Wang, Robert E Eckart, J K Harrison, Thomas M. Bashore
    Abstract:

    BACKGROUND AND AIM OF THE STUDY: Inflammation may play a central role in the progression of stenotic valvular heart disease. Serum levels of matrix metalloproteinases (MMPs), markers of extracellular matrix (ECM) turnover and potential markers of active inflammation, have been recently demonstrated in several inflammatory processes. The present study was designed to examine whether systemic evidence of ECM turnover was present in advanced stenotic Mitral Valve disease. METHODS: Serum levels of MMP-1, -3 and -9 were measured in 114 patients with Mitral stenosis referred for percutaneous balloon Mitral Valve Commissurotomy, and compared to those in 48 healthy, age- and gender-matched controls. RESULTS: Serum levels of MMP-1, -3 and -9 did not vary according to hemodynamic profile or heart failure class at the time of blood sampling. Levels of MMP-1 and -3 were not significantly different between those patients with Mitral stenosis and controls. The level of MMP-9 was significantly higher in patients with Mitral stenosis than in controls, and did not appear to be altered by Commissurotomy. CONCLUSION: Serum levels of MMP-9 were elevated in patients with Mitral stenosis, providing further evidence that inflammation and ECM remodeling plays an important role in the pathophysiology of valvular heart disease.

  • usefulness of percutaneous balloon Mitral Commissurotomy in preventing the development of atrial fibrillation in patients with Mitral stenosis
    American Journal of Cardiology, 2004
    Co-Authors: Richard A Krasuski, Manish D Assar, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Thomas M. Bashore
    Abstract:

    A prospective cohort of patients with Mitral stenosis and no history of atrial arrhythmias showed no decrease in the incidence of atrial fibrillation (AF) after successful versus unsuccessful Inoue balloon percutaneous balloon Mitral Valve Commissurotomy. Advanced age and left atrial dimension best predicted which patients developed AF during follow-up, whereas percutaneous balloon Mitral Valve Commissurotomy procedural success and left atrial pressure reduction did not have an impact on incidence of AF.

  • c reactive protein elevation independently influences the procedural success of percutaneous balloon Mitral Valve Commissurotomy
    American Heart Journal, 2003
    Co-Authors: Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Anneke C Bush, Charles E Mayes, Judy Fleming, Thomas M. Bashore
    Abstract:

    Abstract Background Markers of systemic inflammation including C-reactive protein (CRP) appear to predict morbidity and mortality in various clinical conditions. The presence of systemic inflammation and its impact on the procedural success of percutaneous balloon Mitral Valve Commissurotomy (PBMC) in patients with rheumatic Mitral stenosis has not been previously demonstrated. Methods Measurements of CRP with a high-sensitivity assay were performed at the time of PBMC or during post-procedural follow-up in 119 patients with Mitral stenosis of rheumatic morphology. Patients were questioned to exclude confounders of CRP elevation and categorized into undetectable (≤0.10 mg/L) and detectable (>0.10 mg/L) CRP levels. Detectable levels were further classified into assay range (>0.10 and ≤6.0 mg/L) and elevated (>6.0 mg/L). Results CRP was detectable in 76% of patients and elevated (>6.0 mg/L) in 36% of patients studied. Procedural success occurred in 89% of patients with undetectable CRP, as compared with only 67% in patients with detectable CRP (P = .028). This effect remained after controlling for age and Valve score (previously described predictors of PBMC success). Conclusions Systemic inflammation is common in patients with rheumatic Mitral Valve stenosis, and the relationship between procedural success and CRP suggests persistent inflammation may affect the results of PBMC.

Richard A Krasuski - One of the best experts on this subject based on the ideXlab platform.

  • peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon Mitral Valve Commissurotomy
    Journal of Heart Valve Disease, 2006
    Co-Authors: R J Garr, Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Andrew Wang, Robert E Eckart, J K Harrison, Thomas M. Bashore
    Abstract:

    BACKGROUND AND AIM OF THE STUDY: Inflammation may play a central role in the progression of stenotic valvular heart disease. Serum levels of matrix metalloproteinases (MMPs), markers of extracellular matrix (ECM) turnover and potential markers of active inflammation, have been recently demonstrated in several inflammatory processes. The present study was designed to examine whether systemic evidence of ECM turnover was present in advanced stenotic Mitral Valve disease. METHODS: Serum levels of MMP-1, -3 and -9 were measured in 114 patients with Mitral stenosis referred for percutaneous balloon Mitral Valve Commissurotomy, and compared to those in 48 healthy, age- and gender-matched controls. RESULTS: Serum levels of MMP-1, -3 and -9 did not vary according to hemodynamic profile or heart failure class at the time of blood sampling. Levels of MMP-1 and -3 were not significantly different between those patients with Mitral stenosis and controls. The level of MMP-9 was significantly higher in patients with Mitral stenosis than in controls, and did not appear to be altered by Commissurotomy. CONCLUSION: Serum levels of MMP-9 were elevated in patients with Mitral stenosis, providing further evidence that inflammation and ECM remodeling plays an important role in the pathophysiology of valvular heart disease.

  • usefulness of percutaneous balloon Mitral Commissurotomy in preventing the development of atrial fibrillation in patients with Mitral stenosis
    American Journal of Cardiology, 2004
    Co-Authors: Richard A Krasuski, Manish D Assar, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Thomas M. Bashore
    Abstract:

    A prospective cohort of patients with Mitral stenosis and no history of atrial arrhythmias showed no decrease in the incidence of atrial fibrillation (AF) after successful versus unsuccessful Inoue balloon percutaneous balloon Mitral Valve Commissurotomy. Advanced age and left atrial dimension best predicted which patients developed AF during follow-up, whereas percutaneous balloon Mitral Valve Commissurotomy procedural success and left atrial pressure reduction did not have an impact on incidence of AF.

  • c reactive protein elevation independently influences the procedural success of percutaneous balloon Mitral Valve Commissurotomy
    American Heart Journal, 2003
    Co-Authors: Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Anneke C Bush, Charles E Mayes, Judy Fleming, Thomas M. Bashore
    Abstract:

    Abstract Background Markers of systemic inflammation including C-reactive protein (CRP) appear to predict morbidity and mortality in various clinical conditions. The presence of systemic inflammation and its impact on the procedural success of percutaneous balloon Mitral Valve Commissurotomy (PBMC) in patients with rheumatic Mitral stenosis has not been previously demonstrated. Methods Measurements of CRP with a high-sensitivity assay were performed at the time of PBMC or during post-procedural follow-up in 119 patients with Mitral stenosis of rheumatic morphology. Patients were questioned to exclude confounders of CRP elevation and categorized into undetectable (≤0.10 mg/L) and detectable (>0.10 mg/L) CRP levels. Detectable levels were further classified into assay range (>0.10 and ≤6.0 mg/L) and elevated (>6.0 mg/L). Results CRP was detectable in 76% of patients and elevated (>6.0 mg/L) in 36% of patients studied. Procedural success occurred in 89% of patients with undetectable CRP, as compared with only 67% in patients with detectable CRP (P = .028). This effect remained after controlling for age and Valve score (previously described predictors of PBMC success). Conclusions Systemic inflammation is common in patients with rheumatic Mitral Valve stenosis, and the relationship between procedural success and CRP suggests persistent inflammation may affect the results of PBMC.

Katherine B Kisslo - One of the best experts on this subject based on the ideXlab platform.

  • peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon Mitral Valve Commissurotomy
    Journal of Heart Valve Disease, 2006
    Co-Authors: R J Garr, Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Andrew Wang, Robert E Eckart, J K Harrison, Thomas M. Bashore
    Abstract:

    BACKGROUND AND AIM OF THE STUDY: Inflammation may play a central role in the progression of stenotic valvular heart disease. Serum levels of matrix metalloproteinases (MMPs), markers of extracellular matrix (ECM) turnover and potential markers of active inflammation, have been recently demonstrated in several inflammatory processes. The present study was designed to examine whether systemic evidence of ECM turnover was present in advanced stenotic Mitral Valve disease. METHODS: Serum levels of MMP-1, -3 and -9 were measured in 114 patients with Mitral stenosis referred for percutaneous balloon Mitral Valve Commissurotomy, and compared to those in 48 healthy, age- and gender-matched controls. RESULTS: Serum levels of MMP-1, -3 and -9 did not vary according to hemodynamic profile or heart failure class at the time of blood sampling. Levels of MMP-1 and -3 were not significantly different between those patients with Mitral stenosis and controls. The level of MMP-9 was significantly higher in patients with Mitral stenosis than in controls, and did not appear to be altered by Commissurotomy. CONCLUSION: Serum levels of MMP-9 were elevated in patients with Mitral stenosis, providing further evidence that inflammation and ECM remodeling plays an important role in the pathophysiology of valvular heart disease.

  • usefulness of percutaneous balloon Mitral Commissurotomy in preventing the development of atrial fibrillation in patients with Mitral stenosis
    American Journal of Cardiology, 2004
    Co-Authors: Richard A Krasuski, Manish D Assar, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Thomas M. Bashore
    Abstract:

    A prospective cohort of patients with Mitral stenosis and no history of atrial arrhythmias showed no decrease in the incidence of atrial fibrillation (AF) after successful versus unsuccessful Inoue balloon percutaneous balloon Mitral Valve Commissurotomy. Advanced age and left atrial dimension best predicted which patients developed AF during follow-up, whereas percutaneous balloon Mitral Valve Commissurotomy procedural success and left atrial pressure reduction did not have an impact on incidence of AF.

  • c reactive protein elevation independently influences the procedural success of percutaneous balloon Mitral Valve Commissurotomy
    American Heart Journal, 2003
    Co-Authors: Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Anneke C Bush, Charles E Mayes, Judy Fleming, Thomas M. Bashore
    Abstract:

    Abstract Background Markers of systemic inflammation including C-reactive protein (CRP) appear to predict morbidity and mortality in various clinical conditions. The presence of systemic inflammation and its impact on the procedural success of percutaneous balloon Mitral Valve Commissurotomy (PBMC) in patients with rheumatic Mitral stenosis has not been previously demonstrated. Methods Measurements of CRP with a high-sensitivity assay were performed at the time of PBMC or during post-procedural follow-up in 119 patients with Mitral stenosis of rheumatic morphology. Patients were questioned to exclude confounders of CRP elevation and categorized into undetectable (≤0.10 mg/L) and detectable (>0.10 mg/L) CRP levels. Detectable levels were further classified into assay range (>0.10 and ≤6.0 mg/L) and elevated (>6.0 mg/L). Results CRP was detectable in 76% of patients and elevated (>6.0 mg/L) in 36% of patients studied. Procedural success occurred in 89% of patients with undetectable CRP, as compared with only 67% in patients with detectable CRP (P = .028). This effect remained after controlling for age and Valve score (previously described predictors of PBMC success). Conclusions Systemic inflammation is common in patients with rheumatic Mitral Valve stenosis, and the relationship between procedural success and CRP suggests persistent inflammation may affect the results of PBMC.

Andrew Wang - One of the best experts on this subject based on the ideXlab platform.

  • peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon Mitral Valve Commissurotomy
    Journal of Heart Valve Disease, 2006
    Co-Authors: R J Garr, Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Andrew Wang, Robert E Eckart, J K Harrison, Thomas M. Bashore
    Abstract:

    BACKGROUND AND AIM OF THE STUDY: Inflammation may play a central role in the progression of stenotic valvular heart disease. Serum levels of matrix metalloproteinases (MMPs), markers of extracellular matrix (ECM) turnover and potential markers of active inflammation, have been recently demonstrated in several inflammatory processes. The present study was designed to examine whether systemic evidence of ECM turnover was present in advanced stenotic Mitral Valve disease. METHODS: Serum levels of MMP-1, -3 and -9 were measured in 114 patients with Mitral stenosis referred for percutaneous balloon Mitral Valve Commissurotomy, and compared to those in 48 healthy, age- and gender-matched controls. RESULTS: Serum levels of MMP-1, -3 and -9 did not vary according to hemodynamic profile or heart failure class at the time of blood sampling. Levels of MMP-1 and -3 were not significantly different between those patients with Mitral stenosis and controls. The level of MMP-9 was significantly higher in patients with Mitral stenosis than in controls, and did not appear to be altered by Commissurotomy. CONCLUSION: Serum levels of MMP-9 were elevated in patients with Mitral stenosis, providing further evidence that inflammation and ECM remodeling plays an important role in the pathophysiology of valvular heart disease.

  • usefulness of percutaneous balloon Mitral Commissurotomy in preventing the development of atrial fibrillation in patients with Mitral stenosis
    American Journal of Cardiology, 2004
    Co-Authors: Richard A Krasuski, Manish D Assar, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Thomas M. Bashore
    Abstract:

    A prospective cohort of patients with Mitral stenosis and no history of atrial arrhythmias showed no decrease in the incidence of atrial fibrillation (AF) after successful versus unsuccessful Inoue balloon percutaneous balloon Mitral Valve Commissurotomy. Advanced age and left atrial dimension best predicted which patients developed AF during follow-up, whereas percutaneous balloon Mitral Valve Commissurotomy procedural success and left atrial pressure reduction did not have an impact on incidence of AF.

  • c reactive protein elevation independently influences the procedural success of percutaneous balloon Mitral Valve Commissurotomy
    American Heart Journal, 2003
    Co-Authors: Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Anneke C Bush, Charles E Mayes, Judy Fleming, Thomas M. Bashore
    Abstract:

    Abstract Background Markers of systemic inflammation including C-reactive protein (CRP) appear to predict morbidity and mortality in various clinical conditions. The presence of systemic inflammation and its impact on the procedural success of percutaneous balloon Mitral Valve Commissurotomy (PBMC) in patients with rheumatic Mitral stenosis has not been previously demonstrated. Methods Measurements of CRP with a high-sensitivity assay were performed at the time of PBMC or during post-procedural follow-up in 119 patients with Mitral stenosis of rheumatic morphology. Patients were questioned to exclude confounders of CRP elevation and categorized into undetectable (≤0.10 mg/L) and detectable (>0.10 mg/L) CRP levels. Detectable levels were further classified into assay range (>0.10 and ≤6.0 mg/L) and elevated (>6.0 mg/L). Results CRP was detectable in 76% of patients and elevated (>6.0 mg/L) in 36% of patients studied. Procedural success occurred in 89% of patients with undetectable CRP, as compared with only 67% in patients with detectable CRP (P = .028). This effect remained after controlling for age and Valve score (previously described predictors of PBMC success). Conclusions Systemic inflammation is common in patients with rheumatic Mitral Valve stenosis, and the relationship between procedural success and CRP suggests persistent inflammation may affect the results of PBMC.

Cynthia Pierce - One of the best experts on this subject based on the ideXlab platform.

  • peripheral blood levels of matrix metalloproteinases in patients referred for percutaneous balloon Mitral Valve Commissurotomy
    Journal of Heart Valve Disease, 2006
    Co-Authors: R J Garr, Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Andrew Wang, Robert E Eckart, J K Harrison, Thomas M. Bashore
    Abstract:

    BACKGROUND AND AIM OF THE STUDY: Inflammation may play a central role in the progression of stenotic valvular heart disease. Serum levels of matrix metalloproteinases (MMPs), markers of extracellular matrix (ECM) turnover and potential markers of active inflammation, have been recently demonstrated in several inflammatory processes. The present study was designed to examine whether systemic evidence of ECM turnover was present in advanced stenotic Mitral Valve disease. METHODS: Serum levels of MMP-1, -3 and -9 were measured in 114 patients with Mitral stenosis referred for percutaneous balloon Mitral Valve Commissurotomy, and compared to those in 48 healthy, age- and gender-matched controls. RESULTS: Serum levels of MMP-1, -3 and -9 did not vary according to hemodynamic profile or heart failure class at the time of blood sampling. Levels of MMP-1 and -3 were not significantly different between those patients with Mitral stenosis and controls. The level of MMP-9 was significantly higher in patients with Mitral stenosis than in controls, and did not appear to be altered by Commissurotomy. CONCLUSION: Serum levels of MMP-9 were elevated in patients with Mitral stenosis, providing further evidence that inflammation and ECM remodeling plays an important role in the pathophysiology of valvular heart disease.

  • usefulness of percutaneous balloon Mitral Commissurotomy in preventing the development of atrial fibrillation in patients with Mitral stenosis
    American Journal of Cardiology, 2004
    Co-Authors: Richard A Krasuski, Manish D Assar, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Thomas M. Bashore
    Abstract:

    A prospective cohort of patients with Mitral stenosis and no history of atrial arrhythmias showed no decrease in the incidence of atrial fibrillation (AF) after successful versus unsuccessful Inoue balloon percutaneous balloon Mitral Valve Commissurotomy. Advanced age and left atrial dimension best predicted which patients developed AF during follow-up, whereas percutaneous balloon Mitral Valve Commissurotomy procedural success and left atrial pressure reduction did not have an impact on incidence of AF.

  • c reactive protein elevation independently influences the procedural success of percutaneous balloon Mitral Valve Commissurotomy
    American Heart Journal, 2003
    Co-Authors: Richard A Krasuski, Katherine B Kisslo, Cynthia Pierce, Kevin J Harrison, Andrew Wang, Anneke C Bush, Charles E Mayes, Judy Fleming, Thomas M. Bashore
    Abstract:

    Abstract Background Markers of systemic inflammation including C-reactive protein (CRP) appear to predict morbidity and mortality in various clinical conditions. The presence of systemic inflammation and its impact on the procedural success of percutaneous balloon Mitral Valve Commissurotomy (PBMC) in patients with rheumatic Mitral stenosis has not been previously demonstrated. Methods Measurements of CRP with a high-sensitivity assay were performed at the time of PBMC or during post-procedural follow-up in 119 patients with Mitral stenosis of rheumatic morphology. Patients were questioned to exclude confounders of CRP elevation and categorized into undetectable (≤0.10 mg/L) and detectable (>0.10 mg/L) CRP levels. Detectable levels were further classified into assay range (>0.10 and ≤6.0 mg/L) and elevated (>6.0 mg/L). Results CRP was detectable in 76% of patients and elevated (>6.0 mg/L) in 36% of patients studied. Procedural success occurred in 89% of patients with undetectable CRP, as compared with only 67% in patients with detectable CRP (P = .028). This effect remained after controlling for age and Valve score (previously described predictors of PBMC success). Conclusions Systemic inflammation is common in patients with rheumatic Mitral Valve stenosis, and the relationship between procedural success and CRP suggests persistent inflammation may affect the results of PBMC.